Skip to main content

Table 2 Univariable and multivariable analyses of TTP

From: Genome-wide copy number alteration and VEGFA amplification of circulating cell-free DNA as a biomarker in advanced hepatocellular carcinoma patients treated with Sorafenib

  Univariable analysis Multivariable analysis
Variable N HR (95% CI) p value HR (95% CI) p value
Age, years < 65 125 1 0.736
≥65 26 1.08 (0.69–1.70)  
Sex Male 137 1 0.806
Female 14 0.93 (0.51–1.69)  
ECOG PS 0 52 1 0.158
1–2 99 1.31 (0.90–1.90)  
Etiology HBV 134 1 0.403
Non-HBV 17 1.26 (0.73–2.17)  
Child-Pugh class A 140 1 0.595
B 11 1.20 (0.68–2.38)  
BCLC stage B 5 1 0.191
C 146 2.15 (0.68–6.76)  
MVI No 88 1 0.127
Yes 63 1.32 (0.93–1.87)  
EHS No 15 1 0.090
Yes 136 1.71 (0.92–3.20)  
AFP (ng/mL) < 200 73 1 0.008 1 0.092
≥200 77 1.62 (1.14–2.31)   1.37 (0.95–1.98)  
cfDNA (ng/μL) ≤0.71a) 76 1 0.003 1 0.245
> 0.71a) 75 1.71 (1.20–2.44)   1.27 (0.85–1.88)  
I-score ≤1637a) 76 1 < 0.0001 1 0.011
>1637a) 75 2.09 (1.46–3.00)   1.71 (1.13–2.58)  
  1. HR hazard ratio, CI confidence interval, ECOG PS Eastern Cooperative Oncology Group performance status, HBV hepatitis B virus, BCLC Barcelona Clinic Liver Cancer, MVI macroscopic vascular invasion, EHS extrahepatic spread, AFP alpha fetoprotein, cfDNA cell-free DNA
  2. a)Median value